# of Displayed Technologies: 20 / 21

Applied Category Filter (Click To Remove): Therapeutics


Categories

Analogues of the Epipolythiodioxopiperazine Alkaloids
TS-047118 — Analogues of verticillin which have more useful drug-like properties than the verticillin parent compounds alone, including increased solubility, absorption, and stability, all while maintaining similar anticancer potency to the original compounds.
Verticillins, which are epipolythiodioxopiperazine (ETP) alkaloids, have shown promising anticancer qualities; these fungal metabolites have exhibited high potency against a variety of tumor cell types, with IC50 values typically in the 10-500 nanomolar range. However, these compounds suffer from …
  • College: College of Pharmacy
  • Inventors: Fuchs, James; Huntsman, Andrew
  • Licensing Officer: Ezzell, Janel

mRNA sequence engineering and uses thereof
TS-045448 — Maximized mRNA lifespan and translation for mRNA-based therapy applications.
Many diseases emerge from irregularities that occur during protein synthesis. While limited therapies exist to deliver mature proteins to compensate for these errors, protein therapy by direct protein delivery has limited efficiency. This is due to difficulty in controlling the volume of delivered…
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Zeng, Chunxi
  • Licensing Officer: Ezzell, Janel

Improving immunotherapy with mRNA delivery
TS-045426 — The central mission of cancer immunotherapy treatments is to aid the immune system in detecting and degrading cancer cells. For twenty years, the use of monoclonal antibodies (mAbs) as anti-tumor drugs has been successful in managing cancer disease and increasing patient lifespan. These treatments…
  • College: College of Pharmacy
  • Inventors: Dong, Yizhou; Li, Wenqing; Zhang, Chengxiang
  • Licensing Officer: Ezzell, Janel

Compound 13, an Mps1/TTK Kinase Inhibitor, for Triple Negative Breast Cancer Therapy
TS-037724 — Researchers at The Ohio State University have discovered Compound 13, a patent protected, orally bioavailable and brain penetrant Mps1/TTK inhibitor that exhibits single agent tumor growth inhibition in a murine xenograft model of human triple negative breast cancer upon daily administration.
Breast cancer is a heterogeneous group of tumors, which can be subdivided based on histopathological features, genetic alterations, and gene-expression profiles. Approximately 50-60% of all breast cancer patients and two-thirds of postmenopausal breast cancer patients have estrogen receptor positi…
  • College: College of Pharmacy
  • Inventors: Brueggemeier, Robert; Fisk, Harold; Li, Chenglong; Li, Pui-Kai "Tom"; Sugimoto, Yasuro
  • Licensing Officer: Davis, Stewart

Phyllanthusmin and acutissimalignan A compound derivatives for anticancer and immunostimulation
TS-037721 — A group of potential antitumor arylnapthalene lactone derivatives, which may be developed as novel anticancer and immunostimulant agents.
Natural products and semi-synthetic derivatives derived from them have been used for anticancer drugs or drug leads for many years. However, side-effects such as myelosuppression and secondary leukemia have been reported. Furthermore, these natural products can be difficult to use for targeting sp…
  • College: College of Pharmacy
  • Inventors: Kinghorn, Alan "Dr. A. Douglas Kinghorn"; Fuchs, James; Huntsman, Andrew
  • Licensing Officer: Ezzell, Janel

STAT3 Inhibitors and Their Anti-Cancer Usage
TS-037671 — Novel non-peptidomimetic molecules for use as anti-cancer inhibitors of signal transducer and activator of transcription 3.
The search for more potent drug delivery candidates for cancer therapy remains a challenge within the medical community. Efforts to target cancer at the genetic level have led to numerous discoveries, including the role that constitutive activation of signal transducer and activator of transcripti…
  • College: College of Pharmacy
  • Inventors: Li, Chenglong; Lin, Jiayuh; Yu, Wenying
  • Licensing Officer: Ezzell, Janel

Novel Small-Molecule Integrin-linked Kinase/Phosphoinositide-dependent Protein Kinase-2 Inhibitors
TS-037647 — A novel set of molecules that inhibit integrin-linked kinase in order to suppress tumor cell growth and metastasis.
The Akt signaling pathway is responsible for apoptosis, cell proliferation, and metabolism. In tumor cells, this pathway is up-regulated and aids in promoting cancer cell survival. Complete activation of Akt pathway requires phosphorylation at two amino-acid residues, which are phosporylated by se…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Kulp, Samuel; Lee, Su-Lin
  • Licensing Officer: Paschall, Christopher

Development of STAT3 dimerization inhibitors for cancers
TS-037569 — The constant activation of Signal Transducer and Activator of Transcription 3 (STAT3) is frequently detected in many cancer patients with advanced diseases. About 80% of all cancers overexpress STAT3, including solid tumors, lymphoma, and leukemia. Constant activation of STAT3 activities in nonmal…
  • College: College of Pharmacy
  • Inventors: Li, Pui-Kai "Tom"; Li, Chenglong; Lin, Jiayuh
  • Licensing Officer: Ezzell, Janel

Novel bacterial Type II topoisomerase inhibitors for the treatment of bacterial infections
TS-037293 — Bacterial infections such as sexually transmitted diseases, meningitis, pneumonia, tuberculosis (TB), and tetanus are some of the most common infectious diseases. However, there are few drugs that can be used against all of these diseases, and several bacteria have developed resistance to many com…
  • College: College of Pharmacy
  • Inventors: Mitton-Fry, Mark
  • Licensing Officer: Ezzell, Janel

New anthracycline analogues to overcome multidrug resistance
TS-015117 — Analogues therapy to overcome multi-drug resistance in cancer cells
The Need Daunorubicin is the standard anthracycline agent, a class of anti-tumor compounds used widely in the treatment of a variety of cancers. As multiple drug resistance and toxicity are serious clinical problems associated with daunorubicin, researchers have focused on improving this common …
  • College: College of Pharmacy
  • Inventors: Sun, Duxin; Fang, Lanyan; Wang, Peng George; Zhang, Guisheng
  • Licensing Officer: Ezzell, Janel

Small-Molecule Cyclin D1 Ablative Agents for Breast Cancer Therapy
TS-015102 — A new class of small-molecule cyclin D1 ablative agents based on troglitazone (TG) that repress intracellular cyclin D1 levels.
Cyclin D1 represents an important downstream effector of diverse proliferative and transforming signaling pathways. In mammary cells, transcriptional activation of Cyclin D1 leads to G1/S phase progression and increased proliferation. Cyclin D1 overexpression has been implicated in oncogene-induce…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Huang, Jui-Wen
  • Licensing Officer: Paschall, Christopher

Novel Small-Molecule Protein Phosphatase 2A-Activating Agents
TS-015100 — Activation of protein phosphatase 2-A (PP2A) as a target for anticancer therapy with small molecules.
Previous work indicates that vitamin E succinate (VES) induces apoptosis in different types of cancers cells without significant toxicity to normal cells. Despite advances in the pre-clinical translation of VES in cancer therapy, the mechanisms underlying the effect of this redox-inactive vitamin …
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Kulp, Samuel; Wang, Dasheng
  • Licensing Officer: Paschall, Christopher

New Energy Restriction-Mimetic Agents for Cancer Treatment
TS-015097 — Development of thiazolidinedione (TZD), OSU-CG12, as a novel energy restriction-mimetic agent for cancer therapy and chemo-prevention.
Cancer cells shift cellular metabolism to aerobic glycolysis to gain growth advantages in microenvironments, which has raised interest in therapies that exploit the response of malignant versus normal cells to glycolytic inhibition. Chronic energy restriction is difficult to implement as a chemo-p…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih
  • Licensing Officer: Paschall, Christopher

DNA Methylation Inhibitors
TS-015096 — A set of novel DNA methylation inhibitors that reduce DNA methylation by small molecule agents.
Substantial evidence indicates that DNA methylation-mediated silencing of tumor suppressor genes is a mechanism for the pathogenesis of cancer and many other diseases. Thus, small-molecule agents that target DNA methylation are considered a therapeutically relevant strategy for cancer treatment. T…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Hsiao, Shu-Huei; Leu, Yu-Wei; Shaw, Arthur
  • Licensing Officer: Paschall, Christopher

Estrogen Receptor Beta Agonist Compounds
TS-015086 — Estrogen Receptor Beta Agonists for the treatment of breast, colon, and prostate cancers as well as inflammatory diseases.
There is a large emphasis on the need for novel and more effective cancer therapeutics, since there were nearly 600,000 cancer deaths in the United States in 2016 alone. One method for therapy of prostate, breast, and colon cancer that has been gaining traction is the targeting of estrogen recepto…
  • College: College of Pharmacy
  • Inventors: Tjarks, Werner; Bartunek, Petr; Sedlak, David
  • Licensing Officer: Ezzell, Janel

Cell Adhesion Inhibition
TS-015078 — Exposing cancer cells to poor cell adhesion environments via small molecule agents as a strategy to improve clinical outcomes of several solid malignancies.
The National Cancer Institute estimates that 1.7 million new cases of cancer are diagnosed each year. Substantial evidence indicates that cell adhesion is critical to the development of different aspects of malignant cancer cells, including survival, invasion, metastasis, and drug resistance. Cons…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Kulp, Samuel; Wang, Dasheng
  • Licensing Officer: Paschall, Christopher

Small Molecule AR-Ablative Agents
TS-014842 — A new strategy for using androgen receptor ablative agents has been developed for prostate cancer therapy.
Hormone-refractory prostate cancer is incurable, and patients with this disease have few treatment options. Dysregulation of the androgen receptor (AR) is a hallmark of this incurable cancer. Molecular changes during cancer enhance AR sensitivity or permit AR activation by antiestrogen so that pro…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Wang, Dasheng; Yang, Jian
  • Licensing Officer: Paschall, Christopher

Novel Indole-3-Carbinol-Derived Antitumor Agents
TS-014815 — An anti-tumor agent developed from indol-3-carbinol, a naturally occurring phytochemical in cruciferous vegetables.
According to the Center for Disease Control and Prevention, cancer is the second leading cause of death in the US at approximately 600,000 deaths per year. In addition, the National Cancer Institute estimates that nearly 1.7 million cases of cancer are diagnosed each year. A report from U.S. News …
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Weng, Jing-ru
  • Licensing Officer: Paschall, Christopher

Novel Protein Kinase C Delta Activators
TS-014754 — A novel anti-cancer agent (OSU-2S) that is devoid of S1P1 receptor activity and is highly effective in suppressing hepatocellular carcinoma tumor growth in vivo.
The third leading cause of cancer death worldwide is hepatocellular carcinoma (HCC). Due to the rise in the incidence of hepatitis C virus infection, HCC is expected to increase in the United States. Many patients with HCC are not candidates for surgery because of the location or size of their tum…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Byrd, John; Kulp, Samuel; Muthusamy, Natarajan; Wang, Dasheng
  • Licensing Officer: Ezzell, Janel

Glucose Transporter Inhibitors (GLUT1 Inhibitors)
TS-014734 — A potential cancer treatment that suppresses the ability for cancer cells to intake glucose, thereby hampering cancer cell production.
A fundamental property of neoplastic cells is the shift in cellular metabolism from oxidative phosphorylation to aerobic glycolysis. This glycolytic shift, called the Warburg effect, enables cancer cells to adapt to low-oxygen microenvironments, to generate biosynthetic building blocks for cell pr…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Kulp, Samuel; Wang, Dasheng
  • Licensing Officer: Paschall, Christopher

Show More Technologies

Loading icon